ArticlePsychopharmacology2021
Challenges in CNS drug development and the role of imaging.
Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Baicalin and CNS-related diseases: new insights into neuroprotective potentials based on underlying mechanisms.Biochemistry and biophysics reports · 2026Review
- Multicompartment Drug Monitoring Reveals Paired Brain-Liver Kinetics and Selective Central Nervous System Barrier Permeability in Rats.ACS sensors · 2026Article
- Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors.Advanced drug delivery reviews · 2026Review
- Harnessing brain-derived extracellular vesicles to support RDoC-based drug development.Neuroscience applied · 2025Review
- New epilepsy therapies in development.Nature reviews. Drug discovery · 2024Review
- Translational In Vivo Assays in Behavioral Biology.Annual review of pharmacology and toxicology · 2024Review
- Integrative approach of omics and imaging data to discover new insights for understanding brain diseases.Brain communications · 2024Review
- The Role of Biological Rhythms in New Drug Formulations to Cross the Brain Barriers.International journal of molecular sciences · 2023Review
- Spatiotemporally resolved metabolomics and isotope tracing reveal CNS drug targets.Acta pharmaceutica Sinica. B · 2023Article
- Intraosseous administration into the skull: Potential blood-brain barrier bypassing route for brain drug delivery.Bioengineering & translational medicine · 2023Article
- Experimental Medicine Approaches in Early-Phase CNS Drug Development.Advances in neurobiology · 2023Article
- Engineering circuits of human iPSC-derived neurons and rat primary glia.Frontiers in neuroscience · 2023Article
- Polymer nanocarriers for targeted local delivery of agents in treating brain tumors.Nanotechnology · 2022Review
- Collaboration and knowledge integration for successful brain therapeutics - lessons learned from the pandemic.Disease models & mechanisms · 2022Article
- Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders.Nanomaterials (Basel, Switzerland) · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33860824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.